Clinical Trial Update: Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with apatinib for advanced non-squamous non-small cell lung cancer previously treated with first-line immun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Junling Li | Conditions: Advanced Non Squamous NSCLC | Phase 2 | Status: UNKNOWN